In a regulatory filing on October 20, Samsung Biologics refused to disclose which drugs are commissioned to produce. Under a partnership with GSK in 2020, Samsung Biologics agreed to supply belimumab, which is sold under the trade name Benlysta to treat systemic lupus erythematosus, and supply GSK’s innovative biopharmaceutical therapies, and provide additional capacity for large-scale biopharmaceutical product manufacturing.
GSK has maintained partnerships with other South Korean companies. For the development of a recombinant vaccine, SK Bioscience has used GSK's adjuvant, which is a drug or other substance, or a combination of substances, that is used to increase the efficacy or potency of certain drugs.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.